1
|
Azambuja E, Durbecq V, Rosa DD, Colozza M,
Larsimont D, Piccart-Gebhart M and Cardoso F: HER-2
overexpression/amplification and its interaction with taxane-based
therapy in breast cancer. Ann Oncol. 19:223–232. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
World Health: Organization: W orld Cancer
Report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdfAccessed.
February 26–2011
|
3
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al:
SEER Cancer Statistics Review, 1975-2009. (Vintage 2009
Populations). http://seer.cancer.gov/csr/1975_2009_pops09/Accessed.
May 20–2013
|
4
|
Cancer Facts & Figures 2012. Atlanta:
American Cancer Society. 42012.
|
5
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Khoshnaw SM, Green AR, Powe DG and Ellis
IO: MicroRNA involvement in the pathogenesis and management of
breast cancer. J Clin Pathol. 62:422–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Iorio MV, Casalini P, Piovan C, Di Leva G,
Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E:
MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res.
69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Adams BD, Furneaux H and White BA: The
micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen
receptor-alpha (ERalpha) and represses ERalpha messenger RNA and
protein expression in breast cancer cell lines. Mol Endocrinol.
21:1132–1147. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kondo N, Toyama T, Sugiura H, Fujii Y and
Yamashita H: MiR-206 expression is down-regulated in estrogen
receptor alpha-positive human breast cancer. Cancer Res.
68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang N, Li Q, Feng NH, Cheng G, Guan ZL,
Wang Y, Qin C, Yin CJ and Hua LX: MiR-205 is frequently
downregulated in prostate cancer and acts as a tumor suppressor by
inhibiting tumor growth. Asian J Androl. 15:735–741. 2013.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu H, Zhu S and Mo YY: Suppression of cell
growth and invasion by miR-205 in breast cancer. Cell Res.
19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Slamom DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER-2
for metastatic breast cancer that overexpresses HER-2. J Engl J
Med. 344:783–792. 2001. View Article : Google Scholar
|
18
|
Burris HA: Dual kinase inhibition in the
treatment of breast cancer: initial experience with the EGFR/ErbB-2
inhibitor lapatinib. Oncologist. 9(Suppl 3): 10–15. 2004.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Higa GM and Abraham J: Lapatinib in the
treatment of breast cancer. Expert Rev Anticancer Ther.
7:1183–1192. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
[no authors: listed]:B reast cancer drug
approved for new indication. Womens Health (Lond Engl).
6:1732011.
|
21
|
Kastl L, Brown I and Schofield AC:
MiRNA-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
View Article : Google Scholar : PubMed/NCBI
|